| Drug General Information |
| Drug ID |
D0T5AW
|
| Former ID |
DIB004852
|
| Drug Name |
Desoxypeganine
|
| Synonyms |
Alcoholism therapy, HF Arzneimittelforschung; Desoxypeganine, HF Arzneimittelforschung
|
| Drug Type |
Small molecular drug
|
| Indication |
Alcohol use disorders [ICD9: 303; ICD10:F10.2]
|
Phase 1 |
[1]
|
|---|
| Company |
HF Arzneimittelforschung GmbH & Co KG
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C11H12N2
|
| Canonical SMILES |
N1=C2N(Cc3c1cccc3)CCC2
|
| CAS Number |
CAS 495-59-0
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Acetylcholinesterase |
Target Info |
Modulator |
[1]
|
|---|
| Amine oxidase [flavin-containing] A |
Target Info |
Modulator |
[1]
|
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
|
Dopamine degradation
|
|
Putrescine degradation III
|
|
Noradrenaline and adrenaline degradation
|
|
Serotonin degradation
|
|
Superpathway of melatonin degradation
|
|
Melatonin degradation II
|
|
KEGG Pathway
|
Glycerophospholipid metabolism
|
|
Cholinergic synapsehsa00260:Glycine, serine and threonine metabolism
|
|
Arginine and proline metabolism
|
|
Histidine metabolism
|
|
Tyrosine metabolism
|
|
Phenylalanine metabolism
|
|
Tryptophan metabolism
|
|
Drug metabolism - cytochrome P450
|
|
Metabolic pathways
|
|
Serotonergic synapse
|
|
Dopaminergic synapse
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholism
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Muscarinic acetylcholine receptor 2 and 4 signaling pathway
|
|
Nicotinic acetylcholine receptor signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
5-Hydroxytryptamine degredation
|
|
Dopamine receptor mediated signaling pathway
|
|
Pathway Interaction Database
|
ATF-2 transcription factor network
|
|
PathWhiz Pathway
|
Phospholipid BiosynthesisPW000043:Histidine Metabolism
|
|
Tyrosine Metabolism
|
|
Glycine and Serine Metabolism
|
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
|
WikiPathways
|
Monoamine Transport
|
|
Biogenic Amine Synthesis
|
|
Acetylcholine Synthesis
|
|
Integrated Pancreatic Cancer PathwayWP706:SIDS Susceptibility Pathways
|
|
Oxidative Stress
|
|
Dopamine metabolism
|
|
Phase 1 - Functionalization of compounds
|
|
Neurotransmitter Release Cycle
|
|
Neurotransmitter Clearance In The Synaptic Cleft
|
|
Serotonin Transporter Activity
|
| References |
| REF 1 | Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7. |
|---|
